Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota
Clostridium difficile causes diarrhea and colitis by producing up to three different protein toxins. Here, Tam et al. show that an anthelmintic drug, niclosamide, inhibits the pathogenesis of all three toxins by targeting a host process required for toxin entry into host cells, without disrupting th...
Guardado en:
Autores principales: | John Tam, Therwa Hamza, Bing Ma, Kevin Chen, Greg L. Beilhartz, Jacques Ravel, Hanping Feng, Roman A. Melnyk |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/25196c5f6826491d89346cd290d949ba |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy.
por: Hyun-Jun Kim, et al.
Publicado: (2021) -
Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota
por: Joshua R. Fletcher, et al.
Publicado: (2021) -
Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection
por: Tao Zuo, et al.
Publicado: (2018) -
Gut microbiota composition in health-care facility-and community-onset diarrheic patients with Clostridioides difficile infection
por: Giovanny Herrera, et al.
Publicado: (2021) -
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Mamta Parikh, et al.
Publicado: (2021)